Bonnie van Wilgenburg is a Principal at Monograph. Prior to joining Monograph, Bonnie worked for four years at a leading European venture capital firm, Forbion, where her activities included sourcing, evaluation, deal execution and portfolio management of life science companies. She was a board observer at Inflazome, which was sold to Roche in 2020 for US$450 million plus milestone payments. Before that she worked for a decade as an academic scientist in the fields of immunology, virology and stem cells at Oxford University and the University of Melbourne. She earned her DPhil at Oxford.
Previously, Brandi was an Executive Assistant at TPG. She supported several leaders, including the Co-CEO, Jon Winkelried, TPG Senior Advisors Dr Fred Cohen, Edward Norton, and the Honorable William K. Reilly. Brandi began her career as an assistant working aboard M.Y. Silver Lining. She continued her career at the Santa Fe Film Festival, the Doha Film Institute in Qatar, and the 34th America’s Cup in San Francisco, before moving into private equity and venture capital.
Charles Conn is a Partner and Founder of Monograph. Before co-founding Monograph, Charles was CEO of Oxford Sciences Innovation, a deep science venture firm with approximately £600 million of assets under management formed in partnership with Oxford University. Charles is a technology entrepreneur and former public company CEO (of companies including Ticketmaster, Citysearch and Match.com). He serves as chair of the board of Patagonia and was previously CEO of the Rhodes Trust in Oxford. Previously he was senior advisor to the Gordon & Betty Moore Foundation in San Francisco. He began his career at McKinsey & Company, where he was a Partner. He is a best-selling author on problem solving, and is a member of The Nature Conservancy’s European Council for Global Conservation. Charles is a graduate of Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.
Charlie joined Monograph Capital from Bain and Company, where he worked within the private equity advisory team, with a focus on the healthcare sector. He completed his medical training at Cambridge University and Oxford University prior to practicing at the Royal Free NHS Foundation Trust. Charlie also completed a Master of Public Health at Harvard University as a Fulbright Scholar, and contributed to research as a visiting scientist at the Harvard T.H. Chan School of Public Health.
Fred Cohen is a member of the Investment Committee of Monograph and a Founder of Monograph. Prior to founding Monograph in 2020, Fred Cohen was Co-Founder and Senior Managing Director of Vida Ventures and Partner of TPG and Managing Partner of TPG Biotechnology having joined in 2001 to initiate TPG’s venture efforts in biotechnology and life sciences. Prior to that, Fred Cohen was a Professor of medicine, cellular and molecular pharmacology, biochemistry and biophysics and pharmaceutical chemistry at UCSF. In this context, he was Chief of the Division of Endocrinology and Metabolism and directed an active research program in the areas of prion biology, structure based drug design, bioinformatics and heteropolymer chemistry. Fred Cohen is a Fellow of the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, American College of Physicians, a member of the American Society for Clinical Investigation and the Association of American Physicians, and the recipient of several awards and honors including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize (shared with Stanley Prusiner), a Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation. He graduated magna cum laude from Yale University in 1978 and received his D.Phil from Oxford University as a Rhodes Scholar in 1980, his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and his internal medicine and endocrinology training at UCSF.
Freddie Dear is a Portfolio Principal at Monograph and currently deployed in portfolio company Ascend Gene & Cell Therapies as Vice President of Corporate Development. Prior to Ascend and Monograph, he was a Partner at Syncona, a London based life science focused venture firm, where he was involved in a number of investments, most notably Clade Therapeutics and Quell Therapeutics, where he held board observer roles. Prior to Syncona, he was a member of the investment team at the Wellcome Trust. Freddie holds an undergraduate degree in Biochemistry from the University of Edinburgh.
Jaideep Dudani is a Portfolio Principal at Monograph and leads Portfolio Development at Monograph’s portfolio company, Hi-Bio. He was most recently at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development. Before that, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (which held its initial public offering on the NASDAQ Global Select Market in 2018), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (which held its initial public offering on the NASDAQ Global Select Market in 2019), and Pionyr Immunotherapeutics (which was acquired by Gilead Sciences, Inc. in 2020). He completed his PhD at MIT in Biological Engineering, and holds a BS in Bioengineering from UCLA.
Jo has extensive experience supporting high net worth individuals within private equity, real estate, property and asset management. Prior to joining Monograph, Jo was EA to the Chairman & CEO at James Hambro & Partners. Previously, Jo worked at, Pacific Investments Plc and for a number of boutique property businesses.
Prior to Monograph Capital, Lucinda spent nearly a decade in a range of senior support roles at McKinsey in London. Most recently she has led operations at a successful UK start up. A seasoned, administrative professional, experienced in supporting c-suite executives and high-profile events, across a broad range of functions.
Luke is currently an attending physician-scientist at Memorial Sloan Kettering Cancer Center, where he cares for patients with brain tumors and prostate cancer. He leads a research group focused on the mechanisms of brain metastasis development and conducts prospective clinical trial work utilizing liquid biopsy approaches. Luke previously worked as a Senior Associate at Third Rock Ventures, a biotech-focused early stage venture firm. Luke studied Chemistry and Biochemistry at Memorial University. Luke pursued a D.Phil. in medical oncology at the University of Oxford as a Rhodes Scholar. After leaving Oxford, Luke obtained a medical degree at Yale, and completed his residency training in radiation oncology at the Harvard Radiation Oncology Program.
Melisa joined Monograph Capital from L.E.K. Consulting, where she was an Engagement Manager in the Healthcare and Life Sciences practice, working with biopharma, contract services organisations, diagnostics and research tools providers and investors. She was also a fellow with the World Economic Forum’s Healthcare Industries Platform. She completed her PhD in cancer biology focusing on DNA repair at the Francis Crick Institute, with multiple publications. She also holds a BSc in Biochemistry and MSc in Immunology, from Imperial College London.
Mike LaGatta is a Partner and Chief Operating Officer at Monograph. Prior to joining Monograph, Mike served as the General Counsel of TPG Holdings and Chief Tax Officer of TPG. Mike brings over 20 years of investment management and transactional experience. Mike has a Juris Doctorate and MBA from Georgetown University, a LLM in Taxation from New York University and a Bachelor of Arts in Economics from the University of Texas at Austin.
Having qualified as an ICAEW Chartered Accountant and auditor from PwC’s Insurance and Investment Management practice, Nishat has worked in the finance teams of several not-for-profit organisations. Her most recent role was at the Coalition for Epidemic Preparedness Innovations. Nishat has an Investment Management Certificate from CFA UK and earned a Masters in Biochemistry at Oxford University.
Stephanie heads investor relations for Monograph Capital, overseeing existing LP relationships, fundraising, and strategic marketing efforts for the firm. Prior to joining Monograph in 2023, Stephanie spent over twelve years in business development and investor relations roles across sectors and asset classes including JP Morgan Private Bank, Communities Foundation of Texas, and Capview Partners, a $1.1 billion private equity real estate fund. Stephanie began her career as an Assistant District Attorney for Dallas County District Attorney’s Office in the White Collar Crime Division. Stephanie received her B.B.A in Accounting, M.S.A. in Accounting and her J.D. from Southern Methodist University in Dallas, Texas.
Travis Murdoch is a Partner and co-Founder at Monograph and CEO of portfolio company Human Immunology Biosciences (“Hi-Bio”), a precision immunology company. Prior to Monograph, Travis was a life sciences investor with Softbank Vision Fund, where he oversaw investments in Relay Therapeutics (NASDAQ: RLAY), Vividion Therapeutics (Acqby: BAYRY), Seer (NASDAQ: SEER), VIR (NASDAQ: VIR), Zymergen(NASDAQ: ZY), ElevateBio, Encoded Therapeutics, Insitro, Karius, and Collective Health. He was previously a Principal at Third Rock Ventures, and a consultant at McKinsey & Company. Travis is a gastroenterologist who worked with Northern communities in Canada. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.
Tim Funnell is a Partner and co-Founder at Monograph. Prior to Monograph, Tim was co-founder and Vice President of Operations for MiroBio. Tim has been an investor in the biotechnology and related life sciences industries and company-builder at Syncona, Third Rock Ventures and Oxford Sciences, gaining experience across therapeutic modalities and geographies. Tim leads Monograph’s investments in Aviado and Ascend Gene & Cell Therapies. He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist with an undergraduate degree from University of Cambridge and DPhil from the University of Oxford.
